We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
GlaxoSmithKline (GSK) has reported that they will be out of stock of Rabipur in December 2016 until the end of Q1 2017 and remaining stock will be prioritised for those needing post-exposure treatment. The GSK customer care team can place orders for up to 5 doses of Rabipur for post-exposure use only. Any additional courses needed for post-exposure will need to get GSK internal medical approval.
Sanofi Pasteur MSD have not reported any issues with supply of Rabies Vaccine BP.
